Patent US4798787A successfully refreshed from Google Patents.
US4798787A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Peptide antibodies and their use in detecting oncogene products
Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1984-10-17
•
Granted: 1989-01-17
•
Expires: 2004-10-17
Abstract
Abstract Antibodies exhibit specificity toward single amino acid differences between proteins. These antibodies may be produced by synthesizing a peptide of the appropriate amino acid sequence contained in the protein, immunizing a host with the peptide, and extracting sera from the host to obtain the antibodies. The antibodies and the desired protein are then immunoprecipitated under conditions of partial denaturation to expose the epitope of the protein. The antibodies may be used for diagnostic or therapeutic purposes.
Inventors
- 👤 Francis P. McCormick
- 👤 Gail L. Wong
- 👤 Robin Clark
- 👤 Norman Arnheim
- 👤 Danute E. Nitecki
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:54
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/82; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/531; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/81; Y10S435/961; Y10S436/00; Y10S436/807; Y10S436/808; Y10S436/811; Y10S436/813
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
51 words
A polyclonal antibody preparation that binds selectively to a characteristic marker epitope encompassing amino acid position 12 of an activated form of p21 protein, wherein said polyclonal antibody preparation is specific for a particular amino acid at position 12 and does not bind the p21 protein encoded by the corresponding proto-oncogene.
Claim 2
Dependent Claim
51 words
A polyclonal antibody preparation that binds selectively to a characteristic marker epitope encompassing amino acid position 12 of an activated form of p21 protein, wherein said polyclonal antibody preparation is specific for a particular amino acid at position 12 and does not bind the p21 protein encoded by the corresponding proto-oncogene.
Claim 3
Dependent Claim
28 words
The antibody preparation of claim 1 wherein the amino acid at position 12 is selected from the group consisting of valine, serine, arginine, cysteine, aspartic acid and alanine.
Claim 4
Dependent Claim
12 words
The antibody preparation of claim 2 wherein the amino acid is serine.
Claim 5
Dependent Claim
15 words
The antibody preparation of claim 1 wherein said antibody is an affinity purified polyclonal antibody.
Claim 6
Dependent Claim
13 words
The antibody preparation of claim 1 which is labeled with a detectable label.
Claim 7
Dependent Claim
76 words
An immunogenic peptide fragment of the p21 protein which raises the antibody preparation of claim 1 which comprises an amino acid selected from the group consisting of valine, serine, arginine, cysteine, aspartic acid and alanine at position 12 of the p21 protein, an amount of residues flanking position 12 to define the characteristic marker epitope to which the antibody preparation binds selectively, and a cysteine residue in the penultimate position to the C-terminus of the fragment.
Claim 8
Dependent Claim
27 words
The peptide fragment of claim 6 comprising amino acids 5 to 17 of the p21 protein with said cysteine residue inserted between amino acids 16 and 17.
Claim 9
Dependent Claim
15 words
The peptide fragment of claim 6 conjugated to a carrier protein through the cysteine residue.
Claim 10
Dependent Claim
135 words
A method for detecting an activated form of p21 protein in a cellular sample of a patient which protein has a characteristic marker epitope encompassing amino acid position 12 which is not present in the p21 protein encoded by the corresponding proto-oncogene and which is not exposed in the undenatured protein, which method comprises: (a) treating the sample with a protein denaturing agent that causes the epitope to be exposed and does not substantially inhibit binding of an antibody to the epitope of said protein, (b) incubating the sample with the antibody preparation of claim 5 under conditions that permit the binding of said antibody to said epitope, (c) washing the incubated sample to remove unbound labeled antibody, and (d) detecting the presence of labeled immune complexes of the epitope and antibody in the incubate.
Claim 11
Dependent Claim
12 words
The method of claim 9 wherein the antibody preparation is affinity purified.
Claim 12
Dependent Claim
30 words
The peptide fragment of claim 6 of the formula: LYS--LEU--VAL--VAL--VAL--GLY--ALA--X--GLY--VAL--GLY--LYS--CYS--SER, where X is an amino acid selected from the group consisting of valine, serine, arginine, cysteine, aspartic acid, and alanine.
Claim 13
Dependent Claim
50 words
The method of claim 9 further comprising the step of incubating the sample with an immobilized polyclonal antibody preparation that binds selectively to said epitope under conditions that permit the binding of said antibody to said epitope, wherein the presence of labeled immobilized immune complexes is detected in the incubate.
Claim 14
Dependent Claim
92 words
An inhibiting agent capable of binding selectively to a region of an activated form of p21 protein encoded by an oncogene containing a characteristic marker epitope encompassing amino acid position 12 wherein said polyclonal antibody preparation is specific for a particular amino acid at position 12 and does not bind the p21 protein encoded by the corresponding proto-oncogene, which inhibiting agent has a direct effect on the binding of said p21 protein encoded by said oncogene to a cellular component necessary for the oncogenic activity of said protein encoded by said oncogene.
Claim 15
Dependent Claim
92 words
An inhibiting agent capable of binding selectively to a region of an activated form of p21 protein encoded by an oncogene containing a characteristic marker epitope encompassing amino acid position 12 wherein said polyclonal antibody preparation is specific for a particular amino acid at position 12 and does not bind the p21 protein encoded by the corresponding proto-oncogene, which inhibiting agent has a direct effect on the binding of said p21 protein encoded by said oncogene to a cellular component necessary for the oncogenic activity of said protein encoded by said oncogene.
Claim 16
Dependent Claim
41 words
A partially denatured activated form of p21 protein having a characteristic marker epitope encompassing amino acid position 12 that is not exposed in the undenatured protein, which partially denatured p21 protein is characterized by being denatured sufficiently to expose said epitope.
Claim 17
Dependent Claim
41 words
A partially denatured activated form of p21 protein having a characteristic marker epitope encompassing amino acid position 12 that is not exposed in the undenatured protein, which partially denatured p21 protein is characterized by being denatured sufficiently to expose said epitope.
Claim 18
Dependent Claim
54 words
A process for preparing the partially denatured protein of claim 14 from an undenatured p21 protein comprising contacting the undenatured p21 protein with a protein denaturing agent under conditions which expose the characteristic marker epitope of the undenatured protein but do not substantially inhibit binding of an antibody to the epitope of said protein.
Claim 19
Dependent Claim
112 words
A test kit for conducting an immunometric assay for detecting a characteristic marker epitope encompassing amino acid position 12 of an activated form of p21 protein, comprising, in packaged combination, a multicontainer unit having: (a) a container containing a polyclonal antibody preparation that binds selectively to a characteristic marker epitope encompassing amino acid position 12 of an activated form of p21 protein wherein said polyclonal antibody preparation is specific for a particular amino acid at position 12 and does not bind the p21 protein encoded by the corresponding proto-oncogene, (b) a container containing a denaturing buffer, and (c) a container containing a labeled antibody which binds to the antibody preparation of (a).
Claim 20
Dependent Claim
112 words
A test kit for conducting an immunometric assay for detecting a characteristic marker epitope encompassing amino acid position 12 of an activated form of p21 protein, comprising, in packaged combination, a multicontainer unit having: (a) a container containing a polyclonal antibody preparation that binds selectively to a characteristic marker epitope encompassing amino acid position 12 of an activated form of p21 protein wherein said polyclonal antibody preparation is specific for a particular amino acid at position 12 and does not bind the p21 protein encoded by the corresponding proto-oncogene, (b) a container containing a denaturing buffer, and (c) a container containing a labeled antibody which binds to the antibody preparation of (a).
Claim 21
Dependent Claim
96 words
A test kit for conducting an immunometric assay for detecting a characteristic marker epitope encompassing amino acid position 12 of an activated form of p21 protein, comprising, in packaged combination, a multicontainer unit having: (a) a container containing a polyclonal antibody preparation that binds selectively to a characteristic marker epitope encompassing amino acid position 12 of an activated form of p21 protein wherein said polyclonal antibody preparation is specific for a particular amino acid at position 12 and does not bind the p21 protein encoded by the corresponding proto-oncogene, (b) a container containing a denaturing buffer.
Claim 22
Dependent Claim
96 words
A test kit for conducting an immunometric assay for detecting a characteristic marker epitope encompassing amino acid position 12 of an activated form of p21 protein, comprising, in packaged combination, a multicontainer unit having: (a) a container containing a polyclonal antibody preparation that binds selectively to a characteristic marker epitope encompassing amino acid position 12 of an activated form of p21 protein wherein said polyclonal antibody preparation is specific for a particular amino acid at position 12 and does not bind the p21 protein encoded by the corresponding proto-oncogene, (b) a container containing a denaturing buffer.
Claim 23
Dependent Claim
16 words
The kit of claim 16 wherein the component (a) antibody preparation is an affinity purified antibody.
Claim 24
Dependent Claim
14 words
The kit of claim 17 wherein the antibody preparation is an affinity purified antibody.
Claim 25
Dependent Claim
30 words
The kit of claim 17 further comprising: (d) a container containing an unlabeled antibody directed against a different epitope than the component (a) antibody and immobilized on a solid support.
Claim 26
Dependent Claim
9 words
The kit of claim 20 further comprising a control.
Claim 27
Dependent Claim
27 words
The kit of claim 21 wherein the amino acid at position 12 is selected from the group consisting of valine, serine, arginine, cysteine, aspartic acid and alanine.
Claim 28
Dependent Claim
161 words
A method for detecting an activated form of p21 protein encoded by an oncogene in a cellular sample of a patient which protein has a characteristic marker epitope encompassing amino acid position 12 which is not present in the p21 protein encoded by the corresponding proto-oncogene and which is not exposed in the undenatured protein, which method comprises: (a) treating the sample with a protein denaturing agent that causes the epitope to be exposed and does not substantially inhibit binding of an antibody to the epitope of said protein, (b) incubating the sample with the antibody of claim 1 under conditions that permit the binding of said antibody preparation to said epitope, (c) incubating the sample with a labeled antibody which binds specifically to the antibody employed in step (b), (d) washing the incubated sample to remove unbound labeled antibody, and (e) detecting the presence of labeled immune complexes of the epitope with the antibodies employed in steps (b) and (c).
References Cited (Backward Citations)
WO1984001389A1
Cited
US4535058A
Cited
EP0108564A1
Cited
US4699877A
Cited
EP0119702A2
Cited
WO1984003564A1
Cited
WO1985000807A1
Cited
US4658022A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-01-17 | 1992-07-18 | 1993-01-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-01-17 | 1996-07-18 | 1997-01-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-01-17 | 2000-07-18 | 2001-01-17 | $7700.00 | Window Closed / Lapsed |